Atritech lands $22m in financing:
This article was originally published in Clinica
Executive Summary
Developer of the Watchman left atrial appendage system Atritech has closed a $22m round of financing. This round, which was led by SightLine Partners, brings Atritech's total funding over the last 18 months to $45m. The Plymouth, Minnesota-based firm said it will use the proceeds to complete clinical trials of its lead product, which is designed to prevent patients with atrial fibrillation from suffering a stroke by keeping blood clots from forming in the heart.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.